Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting

Trevor McKibbin, Chris Frei, Rebecca E. Greene, Peter Kwan, Jody Simon, Jim M. Koeller

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background. The clinical trials on which the treatment of advanced colorectal (CRC) is based enroll few elderly patients. Furthermore, few investigations have determined the use and outcomes of the treatment of advanced CRC in practice. This study evaluated the treatment of advanced CRC in community oncology practices, focusing on age-related differences in treatment and outcome. Methods. A national, retrospective chart review was conducted to evaluate the management of advanced CRCin 10 community practices across the U.S. All medical records of patients diagnosed with advanced CRC initiating chemotherapy treatment after January 1, 2003 through 2006 were included. The primary aim was to compare the proportion receiving doublet chemotherapy (irinotecan or oxaliplatin with a fluoropyrimi- dine) as initial therapy in young (age ≤65 years) and elderly (age >65 years) patients. Additional aims included age-based comparisons of the addition of bevacizumab to chemotherapy, overall chemotherapy use, allcause mortality, and toxicity-related events. Results. Overall, 520 patients (56% elderly) received 6,253 cycles of chemotherapy. Of the younger patients, 84% received doublet chemotherapy first-line, compared with 58% of elderly patients (p < .001). The use of each of the medications-irinotecan, oxaliplatin, and bevacizumab - was lower in elderly patients (p < .001). Independent predictors of a higher risk for mortality were age >65 (adjusted hazards ratio [HR],1.19; 95% confidence interval [CI], 1.02-1.39) and performance status score ≥2 (HR, 1.65; 95% CI, 1.41-1.91). Conclusion. Elderly patients are less likely to receive first-line doublet chemotherapy than younger patients. Age and performance status are independent predictors of treatment and overall survival.

Original languageEnglish (US)
Pages (from-to)876-885
Number of pages10
JournalOncologist
Volume13
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Colorectal Neoplasms
Monoclonal Antibodies
Drug Therapy
oxaliplatin
irinotecan
Therapeutics
Confidence Intervals
Medical Records
Clinical Trials
Survival
Mortality

Keywords

  • Bevacizumab
  • Colorectal cancer
  • Disparity
  • Elderly
  • Irinotecan
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. / McKibbin, Trevor; Frei, Chris; Greene, Rebecca E.; Kwan, Peter; Simon, Jody; Koeller, Jim M.

In: Oncologist, Vol. 13, No. 8, 08.2008, p. 876-885.

Research output: Contribution to journalArticle

McKibbin, Trevor ; Frei, Chris ; Greene, Rebecca E. ; Kwan, Peter ; Simon, Jody ; Koeller, Jim M. / Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. In: Oncologist. 2008 ; Vol. 13, No. 8. pp. 876-885.
@article{dfe68ad532f5456f9e8c6a39dd2eac00,
title = "Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting",
abstract = "Background. The clinical trials on which the treatment of advanced colorectal (CRC) is based enroll few elderly patients. Furthermore, few investigations have determined the use and outcomes of the treatment of advanced CRC in practice. This study evaluated the treatment of advanced CRC in community oncology practices, focusing on age-related differences in treatment and outcome. Methods. A national, retrospective chart review was conducted to evaluate the management of advanced CRCin 10 community practices across the U.S. All medical records of patients diagnosed with advanced CRC initiating chemotherapy treatment after January 1, 2003 through 2006 were included. The primary aim was to compare the proportion receiving doublet chemotherapy (irinotecan or oxaliplatin with a fluoropyrimi- dine) as initial therapy in young (age ≤65 years) and elderly (age >65 years) patients. Additional aims included age-based comparisons of the addition of bevacizumab to chemotherapy, overall chemotherapy use, allcause mortality, and toxicity-related events. Results. Overall, 520 patients (56{\%} elderly) received 6,253 cycles of chemotherapy. Of the younger patients, 84{\%} received doublet chemotherapy first-line, compared with 58{\%} of elderly patients (p < .001). The use of each of the medications-irinotecan, oxaliplatin, and bevacizumab - was lower in elderly patients (p < .001). Independent predictors of a higher risk for mortality were age >65 (adjusted hazards ratio [HR],1.19; 95{\%} confidence interval [CI], 1.02-1.39) and performance status score ≥2 (HR, 1.65; 95{\%} CI, 1.41-1.91). Conclusion. Elderly patients are less likely to receive first-line doublet chemotherapy than younger patients. Age and performance status are independent predictors of treatment and overall survival.",
keywords = "Bevacizumab, Colorectal cancer, Disparity, Elderly, Irinotecan, Oxaliplatin",
author = "Trevor McKibbin and Chris Frei and Greene, {Rebecca E.} and Peter Kwan and Jody Simon and Koeller, {Jim M.}",
year = "2008",
month = "8",
doi = "10.1634/theoncologist.2008-0061",
language = "English (US)",
volume = "13",
pages = "876--885",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "8",

}

TY - JOUR

T1 - Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting

AU - McKibbin, Trevor

AU - Frei, Chris

AU - Greene, Rebecca E.

AU - Kwan, Peter

AU - Simon, Jody

AU - Koeller, Jim M.

PY - 2008/8

Y1 - 2008/8

N2 - Background. The clinical trials on which the treatment of advanced colorectal (CRC) is based enroll few elderly patients. Furthermore, few investigations have determined the use and outcomes of the treatment of advanced CRC in practice. This study evaluated the treatment of advanced CRC in community oncology practices, focusing on age-related differences in treatment and outcome. Methods. A national, retrospective chart review was conducted to evaluate the management of advanced CRCin 10 community practices across the U.S. All medical records of patients diagnosed with advanced CRC initiating chemotherapy treatment after January 1, 2003 through 2006 were included. The primary aim was to compare the proportion receiving doublet chemotherapy (irinotecan or oxaliplatin with a fluoropyrimi- dine) as initial therapy in young (age ≤65 years) and elderly (age >65 years) patients. Additional aims included age-based comparisons of the addition of bevacizumab to chemotherapy, overall chemotherapy use, allcause mortality, and toxicity-related events. Results. Overall, 520 patients (56% elderly) received 6,253 cycles of chemotherapy. Of the younger patients, 84% received doublet chemotherapy first-line, compared with 58% of elderly patients (p < .001). The use of each of the medications-irinotecan, oxaliplatin, and bevacizumab - was lower in elderly patients (p < .001). Independent predictors of a higher risk for mortality were age >65 (adjusted hazards ratio [HR],1.19; 95% confidence interval [CI], 1.02-1.39) and performance status score ≥2 (HR, 1.65; 95% CI, 1.41-1.91). Conclusion. Elderly patients are less likely to receive first-line doublet chemotherapy than younger patients. Age and performance status are independent predictors of treatment and overall survival.

AB - Background. The clinical trials on which the treatment of advanced colorectal (CRC) is based enroll few elderly patients. Furthermore, few investigations have determined the use and outcomes of the treatment of advanced CRC in practice. This study evaluated the treatment of advanced CRC in community oncology practices, focusing on age-related differences in treatment and outcome. Methods. A national, retrospective chart review was conducted to evaluate the management of advanced CRCin 10 community practices across the U.S. All medical records of patients diagnosed with advanced CRC initiating chemotherapy treatment after January 1, 2003 through 2006 were included. The primary aim was to compare the proportion receiving doublet chemotherapy (irinotecan or oxaliplatin with a fluoropyrimi- dine) as initial therapy in young (age ≤65 years) and elderly (age >65 years) patients. Additional aims included age-based comparisons of the addition of bevacizumab to chemotherapy, overall chemotherapy use, allcause mortality, and toxicity-related events. Results. Overall, 520 patients (56% elderly) received 6,253 cycles of chemotherapy. Of the younger patients, 84% received doublet chemotherapy first-line, compared with 58% of elderly patients (p < .001). The use of each of the medications-irinotecan, oxaliplatin, and bevacizumab - was lower in elderly patients (p < .001). Independent predictors of a higher risk for mortality were age >65 (adjusted hazards ratio [HR],1.19; 95% confidence interval [CI], 1.02-1.39) and performance status score ≥2 (HR, 1.65; 95% CI, 1.41-1.91). Conclusion. Elderly patients are less likely to receive first-line doublet chemotherapy than younger patients. Age and performance status are independent predictors of treatment and overall survival.

KW - Bevacizumab

KW - Colorectal cancer

KW - Disparity

KW - Elderly

KW - Irinotecan

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=50649094504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649094504&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2008-0061

DO - 10.1634/theoncologist.2008-0061

M3 - Article

C2 - 18695260

AN - SCOPUS:50649094504

VL - 13

SP - 876

EP - 885

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 8

ER -